• About us
• Contact

Advertisement

Organisation › Details

Mendus AB (publ) (Nasdaq Stockholm: IMMU.ST)

Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the Company's most advanced product - INTUVAX® against kidney cancer - has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST). *

 

	Start	2022-06-23 renamed
	Group	Mendus (Group)
	Predecessor	Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Person	Manting, Erik (Immunicum AB 202110 before CEO of DCPrime)
	Person 2	Zeilemaker, Sijme (Immunicum 201703– Director Business Development before InteRNA Technologies + to-BBB Technologies)
	Region	Göteborg (Gothenburg)
	Country	Sweden
	City	n. a.
		Address record changed: 2023-06-08
Basic data	Employees	B: 11 to 50 (2018-12-31)
	Currency	SEK
	Annual sales	184,000 (income, operating (2018) 2018-12-31)
	Profit	-97,860,000 (2018-12-31)
	Cash	443,798,000 (2018-12-31)
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Mendus (Group)

• [1] Immunicum AB. (10/26/21). "Press Release: Immunicum Appoints Lotta Ferm as Chief Financial Officer"....
• [2] Elicera Therapeutics AB. (3/22/21). "Press Release: Elicera Announces Appointment of ATMP Specialist Karin Hoogendoorn to the Board". Gothenburg....
• [3] Immunicum AB. (11/18/20). "Press Release: Immunicum AB and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies"....
• [4] Immunicum AB. (12/13/19). "Press Release: Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO"....
• [5] Immunicum AB. (10/16/18). "Press Release: Immunicum AB (publ) Clarifies Information Regarding Directed Issue [Not for US, AU, CA, et al.]"....
• [6] Immunicum AB. (10/16/18). "Press Release: Notice of Extraordinary General Meeting in Immunicum AB (publ)"....
• [7] Immunicum AB. (10/16/18). "Press Release: Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel - a New and Innovative Cancer Immunotherapy [Not for US, AU, CA, et al...
• [8] Immunicum AB. (9/27/18). "Press Release: Immunicum AB (publ) Announces Upcoming Presentations at Conferences in October"....
• [9] Immunicum AB. (1/31/18). "Press Release: Michaela Gertz Joins Immunicum as CFO"....
• [10] Immunicum AB. (1/15/18). "Press Release: Immunicum AB (publ) Initiates Trading of Shares on Nasdaq Stockholm"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.